UNSPSC 51283919: Sulfamethoxazole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H11N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JE42381TNV, chemically known as 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide but generally known as sulfamethoxazole, which bears US NIH Compound Identifier 5329. European Medicines Agency schedules Sulfamethoxazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10711MIG. The term SULFAMETHOXAZOLE is an International Non-Proprietary Name.

UNSPSC 51283919 Sulfamethoxazole, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two opportunities posted under this code involve pharmaceutical products — one a completed piggyback contract award through a cooperative purchasing vehicle for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), and the other a county bid for Naloxone and drug deactivation systems — neither of which is sulfamethoxazole. State and local procurement offices appear to tag pharmaceutical acquisitions to this code inconsistently, mixing antibiotic and emergency-response drug categories without regard to the specific active ingredient. The work being solicited includes both routine pharmaceutical warehouse supply through consortia and emergency-response drug procurement, but neither represents the targeted antibiotic family the code nominally describes.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 contract through the MMCAP Infuse cooperative to Chartwell Rx LLC on August 28, 2026 (IFB process, response deadline September 11, 2026) for antibiotic supply with 12-month initial term and two renewal options. Seminole County, Florida released an IFB on June 30, 2026 (response deadline July 26, 2023, with quarterly delivery requirements) for Naloxone and drug deactivation systems. Neither recent opportunity represents active demand for sulfamethoxazole itself, and the code's utility as a procurement filter for this pharmaceutical is low. Firms tracking this code should verify whether their product category aligns with how issuing bodies are actually tagging opportunities before investing in competitive response.